CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation
International Journal of Molecular Sciences · 17.11.2026 · 27 (22) · 10329
DOI: 10.3390/ijms272210329 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.11.2026. Verfasst von Myoung Hee Kang und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly desmoplastic and immunosuppressive tumor microenvironment (TME) that limits immune-cell infiltration, impairs antigen presentation, and promotes tumor-supportive myeloid responses. CD40 agonism offers a distinct immunotherapeutic strategy by activating macrophages and antigen-presenting cells (APCs), enhancing antigen presentation, and promoting innate and adaptive antitumor immunity. Preclinical studies have demonstrated macrophage-dependent tumor regression and stromal remodeling, while combination with chemotherapy can enhance antigen release and subsequent immune priming. Clinical studies of CD40 agonists, including sotigalimab, mitazalimab, and selicrelumab, have demonstrated immune and TME remodeling, but consistent survival benefit has not been established in unselected patients. Differences in treatment context, chemotherapy backbone, treatment sequence, and antibody architecture may contribute to variable clinical outcomes. Emerging evidence indicates that limited therapeutic activity may reflect multiple factors, including APC deficiency, persistent immunosuppression, inadequate effector responses, stromal and spatial immune exclusion, and pharmacologic limitations related to Fcγ receptor engagement and systemic toxicity. Future development should therefore emphasize biomarker-guided patient selection, rational treatment sequencing, spatially controlled CD40 activation, and mechanistically matched combination strategies. Integration of immune, molecular, and pharmacodynamic biomarkers, together with next-generation CD40 agonists, may help translate CD40-mediated immune remodeling into more durable clinical benefit in PDAC.
Zitieren
APA
Kang, M. H., Go, S., & Lee, W. S. (2026). CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation. International Journal of Molecular Sciences, 27(22), 10329. https://doi.org/10.3390/ijms272210329
Vancouver
Kang MH, Go S, Lee WS. CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation. International Journal of Molecular Sciences. 2026;27(22):10329. doi:10.3390/ijms272210329
BibTeX
@article{Kang2026,
author = {Kang, Myoung Hee and Go, Se-Il and Lee, Won Sup},
title = {CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10329},
doi = {10.3390/ijms272210329}
}
EUVIMED